Halozyme Therapeutics Inc. (NASDAQ:HALO) shares were up 1.9% during mid-day trading on Friday . The company traded as high as $8.91 and last traded at $8.80, with a volume of 621,528 shares trading hands. The stock had previously closed at $8.64.

A number of research analysts recently issued reports on HALO shares. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 8th. Canaccord Genuity reiterated a “buy” rating and set a $11.00 target price on shares of Halozyme Therapeutics in a research report on Monday, June 6th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $15.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, June 23rd. Finally, Jefferies Group reiterated a “sell” rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $15.68.

The stock’s market capitalization is $1.13 billion. The stock has a 50 day moving average of $9.01 and a 200-day moving average of $9.82.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The firm had revenue of $42.50 million for the quarter, compared to analysts’ expectations of $29.65 million. The business’s quarterly revenue was up 127.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.12) EPS. Equities research analysts expect that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the stock. BB Biotech AG raised its position in shares of Halozyme Therapeutics by 1.4% in the fourth quarter. BB Biotech AG now owns 7,029,832 shares of the biopharmaceutical company’s stock valued at $121,827,000 after buying an additional 100,000 shares in the last quarter. Tekla Capital Management LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $3,466,000. New York State Common Retirement Fund raised its position in shares of Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock valued at $6,460,000 after buying an additional 18,940 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Halozyme Therapeutics by 9.8% in the fourth quarter. ProShare Advisors LLC now owns 122,509 shares of the biopharmaceutical company’s stock valued at $2,123,000 after buying an additional 10,937 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock valued at $4,430,000 after buying an additional 23,600 shares in the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.